DNA vs PMCB
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 23, 2026
DNA
49.5
AI Score
VS
DNA Wins
PMCB
48.8
AI Score
Investment Advisor Scores
PMCB
49score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | DNA | PMCB | Winner |
|---|---|---|---|
| Net Income | -129.30M | -5.08M | PMCB |
| Operating Income | -129.92M | -1.01M | PMCB |
| ROE | -30.8% | -18.5% | PMCB |
| ROA | -13.1% | -13.8% | DNA |
| Total Assets | 990.05M | 36.71M | DNA |
| Cash | 84.53M | 17.74M | DNA |
| Current Ratio | 4.57 | 40.30 | PMCB |
Relative Price Performance (Last 90 Days)
DNA 1M: +13.2%
· 3M: +31.9%
PMCB 1M: -18.3%
· 3M: -41.7%
Current Technical Phase
DNA
NeutralHold
Mixed signals - no dominant trend phase, RSI 45
PMCB
MarkdownSell / avoid
Price below a falling SMA50 (slope -15.9%), weak momentum, RSI 35
Fundamentals Snapshot
| Metric | DNA | PMCB |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -3.4 | 7.0 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.5% | 0.0% |
| Gross Margin | 0.7% | — |
| Operating Margin | -2.8% | 0.0% |
| EPS | -5.06 | -2.31 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, DNA is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.